Gastric Cancer Indication Strategy Report 2026: CLDN18.2, HER2, Trials and Deal Outlook
This report was assembled with PatSnap MCP evidence workflows that connect disease, epidemiology, target, trial and deal intelligence. Explore PatSnap Life Sciences MCP Servers.
Updated July 2026. This indication-specific strategy report is designed for portfolio, search-and-evaluation and business development teams. Counts reflect the returned MCP searches and should be interpreted as landscape signals, not as counts of unique active drugs.
Executive strategy view
Gastric cancer remains a high-mortality global indication in which biomarker-defined therapy is expanding beyond chemotherapy. PatSnap disease_fetch resolved Stomach Cancer and returned 811 development-drug records. The most attractive strategies are not broad all-comer programs, but approaches that use CLDN18.2, HER2, immune markers or molecular subtype to identify patients likely to benefit.
Disease background and epidemiology
Gastric cancers are heterogeneous across anatomic site, histology, viral status and molecular drivers. Treatment decisions increasingly incorporate HER2 expression, PD-L1, microsatellite status and CLDN18.2. Late presentation and rapid progression remain common, while geographic variation affects screening, pathology and the standard treatment backbone.
epidemiology_search retrieved a 2022 estimate of more than 968,000 new cases and nearly 660,000 deaths worldwide, placing gastric cancer among the leading causes of cancer mortality. Although global incidence and mortality have declined, Eastern Asia retains the highest rates. This combination of scale, lethality and regional concentration supports global development with region-specific enrollment planning.
Unmet need
Key needs include durable first-line control, effective treatment after checkpoint or HER2-directed therapy, better options for biomarker-negative disease, reduced toxicity and improved detection. Antigen heterogeneity and loss can limit targeted approaches, and later-line patients often have poor performance status.
At the midpoint of the assessment, MCP tools make it possible to move from disease burden to mechanistic and competitive evidence without breaking the analytical chain. Explore PatSnap Life Sciences MCP Servers.
Target and mechanism rationale
target_fetch confirmed CLDN18.2 and HER2. CLDN18.2 is a lineage-associated tight-junction protein exposed on malignant cells and supports antibodies, ADCs, bispecifics and cell therapy. HER2 is a validated oncogenic and surface target but can show spatial and temporal heterogeneity. Programs should address expression thresholds, assay reproducibility and antigen evolution.
Development thesis
Prioritize a biomarker-defined population and demonstrate why the modality works after current standards. CLDN18.2 programs need evidence across expression ranges and resistance states; HER2 programs should show activity after prior antibody or ADC exposure and account for heterogeneous expression.
Clinical competition
clinical_trial_search returned 3,633 active, recruiting or upcoming records under the gastric-cancer hierarchy, indicating very high competition.
- A Phase 2 study evaluates retlirafusp alfa plus chemotherapy as conversion therapy in gastric or gastroesophageal-junction adenocarcinoma.
- An early Phase 1 imaging study evaluates radionuclide-labeled IR199 for biodistribution and dosimetry.
- A randomized Phase 3 study evaluates QLS31905 combination therapy in unresectable advanced or metastatic disease.
Competition spans checkpoint combinations, CLDN18.2 antibodies and ADCs, HER2-directed agents, bispecifics and cell therapies. Enrollment pressure is greatest in biomarker-positive first-line populations. Differentiation should center on depth, durability, safety and activity after prior targeted therapy.
Deal activity and market attractiveness
drug_deal_search returned eight gastric-cancer-linked transactions from 2023 through July 2026, showing commercial interest across immunotherapy and regional product rights.
- CStone and PharmaLink entered a regional partnership for sugemalimab across the Middle East, North Africa and South Africa.
- Haihe Biopharma and PharmaEngine reached an exclusive Taiwan distribution agreement for oral paclitaxel solution.
- 3SBio and Haihe Biopharma entered a commercialization collaboration for oral paclitaxel.
Market attractiveness is high because of global scale, biomarker expansion and multiple treatment lines. Risk is also high due to crowding and heterogeneous testing. Assets with clear post-targeted-therapy value and deployable diagnostics should be most partnerable.
Indication strategy scorecard
| Dimension | Assessment | Evidence rationale |
|---|---|---|
| Evidence strength | High | Validated HER2 biology and growing CLDN18.2 clinical evidence support biomarker therapy. |
| Unmet need | High | Late diagnosis and metastatic mortality remain substantial. |
| Competitive intensity | Very High | More than 3,600 broad active records indicate heavy development. |
| Deal attractiveness | High | Eight recent indication-linked deals show regional and modality demand. |
| Overall priority | Selective High | Best for biomarker-defined and post-standard-of-care differentiation. |
Recommended positioning
- Select a biomarker and line-of-therapy niche before dose expansion.
- Validate expression assays across primary and metastatic tissue.
- Include Asian sites and region-specific standards in the global plan.
- Generate evidence after prior checkpoint or targeted therapy.
Conclusion
Gastric cancer is a large, lethal and increasingly segmented market. A winning 2026 strategy pairs CLDN18.2 or HER2 biology with a precise clinical sequence, robust diagnostics and evidence that the modality remains active after current standards.
Build your own reproducible indication strategy workflow with connected life-science intelligence. Explore PatSnap Life Sciences MCP Servers.
Method: PatSnap Target & Disease MCP disease_fetch, epidemiology_search and target_fetch; Clinical Trials MCP clinical_trial_search; Company & Deal Intelligence MCP drug_deal_search. Evidence snapshot: July 20, 2026.
